Commence rolling BLA submission for Deramiocel
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 24 Sep 2024
- Due
- 31 Oct 2024
- Delivered
- October 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Plan to commence rolling BLA submission October 2024”
What we found
Evidence strength A What the grades mean
Capricor Therapeutics successfully initiated the rolling BLA submission for deramiocel in October 2024, as confirmed by multiple SEC filings.
-
A Capricor Therapeutics, Inc. 8-K filed 2024-11-13
“Rolling BLA submission initiated in October 2024” ✓ confirmed on the page
-
A Capricor Therapeutics, Inc. 8-K filed 2024-11-13
“Capricor initiated the rolling BLA submission in October of 2024” ✓ confirmed on the page
Market reaction: the shares moved +4.7% against the S&P 500 over the three sessions around the disclosure (12 Nov 2024 to 15 Nov 2024). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +61 days
- 2 versions
-
Version 1 · original · stated 24 Sep 2024
Deadline 31 Oct 2024 (“October 2024”) · wording expected
-
Version 2 · stated 9 Oct 2024
Deadline 31 Dec 2024 (“by the end of 2024”) · wording expected
“Capricor plans to complete its rolling BLA submission by the end of 2024.”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory other
- Indicative materiality
- Medium rules
- Action
- Commence
- Deliverable
- Rolling BLA submission
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Capricor Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-CAPR-002556 · Corrections policy